Launch of the GLYCAGEST project on new glycation markers

Gestational diabetes is associated with an increased risk of macrosomia (birth weight ≥ 4 kg or ≥ 90th percentile for gestational age) and maternal-fetal complications. Glycated hemoglobin, a marker currently used clinically to monitor diabetic pregnant women, poorly predicts this risk, notably due to changes in erythropoiesis during pregnancy.The hypothesis of the GLYCAGEST study, a prospective cohort study, is that new glycation markers, skin autofluorescence and glycated albumin, could better predict the occurrence of gestational diabetes and neonatal macrosomia in pregnant women.

If this is the case, using these new markers will offer an alternative to the current recommendations for screening and monitoring gestational diabetes.
The GLYCAGEST study was launched on 18/12/2023 and will include 800 pregnant women followed at the Bordeaux University Hospital maternity unit.

The principal investigator of this project is Dr Ninon FOUSSARD, Bordeaux University Hospital, Endocrinology-Diabetology-Nutrition Department.
This project is a collaboration between Bordeaux University Hospital and the LEHA team, and is supported by the Société Francophone du Diabète (SFD), the European Foundation for the Study of Diabetes (EFSD) and the FGLMR/AVAD fund of the Fondation Bordeaux Université (FBU).